Skip to main content
Erschienen in: World Journal of Surgery 12/2008

01.12.2008 | Invited Commentary

Surgical Outcome and Prognostic Factors in Intrahepatic Cholangiocarcinoma

verfasst von: Toshio Nakagohri, Taira Kinoshita, Masaru Konishi, Shinichiro Takahashi, Naoto Gotohda

Erschienen in: World Journal of Surgery | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

The clinicopathologic features and surgical outcome of intrahepatic cholangiocarcinoma are not fully understood.

Methods

Fifty-six consecutive patients with intrahepatic cholangiocarcinoma who underwent surgical resection at the National Cancer Center Hospital East between October 1992 and July 2007 were retrospectively analyzed. Intrahepatic cholangiocarcinomas were subdivided into solitary tumors and tumors with intrahepatic metastasis.

Results

Complete tumor removal (R0 resection) was performed in 42 patients (75%). The 5-year survival rate for patients with intrahepatic cholangiocarcinoma (n = 56), patients with a solitary tumor (n = 46), and patients with intrahepatic metastasis (n = 10) were 32, 38, and 0%, respectively. There was a significant difference in survival between patients with a solitary tumor and those with intrahepatic metastasis (p < 0.0001). The 5-year survival rate for patients with stage I (n = 3), II (n = 9), III (n = 15), and IV disease (n = 26) was 100, 67, 37, and 0%, respectively. There was a significant difference in survival between stage I and stage IV (p = 0.011), between stage II and stage IV (p = 0.0002), and between stage III and stage IV (p = 0.0015). The most frequent site of recurrence was the liver. Univariate analysis showed that intrahepatic metastasis, portal vein invasion, hepatic duct invasion, lymph node metastasis, perineural invasion, and positive surgical margin (R1) were significantly associated with poor survival. Multivariate analysis confirmed that intrahepatic metastasis was a significant and independent prognostic indicator after surgical resection for intrahepatic cholangiocarcinoma (p = 0.001). No patient with intrahepatic metastasis survived more than 10 months in this study.

Conclusions

Intrahepatic metastasis was the strongest predictor of poor survival in intrahepatic cholangiocarcinoma.
Literatur
1.
Zurück zum Zitat Ikai I, Arii S, Okazaki M et al (2007) Report of the 17 th nationwide follow-up study of primary liver cancer. Hepatol Res 37:676–691PubMedCrossRef Ikai I, Arii S, Okazaki M et al (2007) Report of the 17 th nationwide follow-up study of primary liver cancer. Hepatol Res 37:676–691PubMedCrossRef
2.
Zurück zum Zitat Wood R, Brewster DH, Fraser LA et al (2003) Do increases in mortality from intrahepatic cholangiocarcinoma reflect a genuine increase in risk? Insights from cancer registry data in Scotland. Eur J Cancer 39:2087–2092PubMedCrossRef Wood R, Brewster DH, Fraser LA et al (2003) Do increases in mortality from intrahepatic cholangiocarcinoma reflect a genuine increase in risk? Insights from cancer registry data in Scotland. Eur J Cancer 39:2087–2092PubMedCrossRef
3.
Zurück zum Zitat Taylor-Robinson SD, Toledano MB, Arora S et al (2001) Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut 48:816–820PubMedCrossRef Taylor-Robinson SD, Toledano MB, Arora S et al (2001) Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut 48:816–820PubMedCrossRef
4.
Zurück zum Zitat Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353–1357PubMedCrossRef Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353–1357PubMedCrossRef
5.
Zurück zum Zitat Welzel TM, Graubard BI, El-Serag HB et al (2007) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 5:1221–1228PubMedCrossRef Welzel TM, Graubard BI, El-Serag HB et al (2007) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 5:1221–1228PubMedCrossRef
6.
Zurück zum Zitat Madariaga JR, Iwatsuki S, Todo S et al (1998) Liver resection for hilar and peripheral cholangiocarcinoma: a study of 62 cases. Ann Surg 227:70–79PubMedCrossRef Madariaga JR, Iwatsuki S, Todo S et al (1998) Liver resection for hilar and peripheral cholangiocarcinoma: a study of 62 cases. Ann Surg 227:70–79PubMedCrossRef
7.
Zurück zum Zitat Weber SM, Jarnagin WR, Klimstra D et al (2001) Inrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 193:384–391PubMedCrossRef Weber SM, Jarnagin WR, Klimstra D et al (2001) Inrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 193:384–391PubMedCrossRef
8.
Zurück zum Zitat Uenishi T, Hirohashi K, Kubo et al (2001) Histological factors affecting prognosis following hepatectomy for intrahepatic cholamgiocarcinoma. World J Surg 25:865–869 Uenishi T, Hirohashi K, Kubo et al (2001) Histological factors affecting prognosis following hepatectomy for intrahepatic cholamgiocarcinoma. World J Surg 25:865–869
9.
Zurück zum Zitat Nakagohri T, Asano T, Kinoshita H et al (2003) Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg 23:289–293CrossRef Nakagohri T, Asano T, Kinoshita H et al (2003) Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg 23:289–293CrossRef
10.
Zurück zum Zitat Tajima Y, Kuroki T, Fukuda K et al (2004) An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg 91:99–104PubMedCrossRef Tajima Y, Kuroki T, Fukuda K et al (2004) An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg 91:99–104PubMedCrossRef
11.
Zurück zum Zitat Urahashi T, Yamamoto M, Ohtsubo T et al (2007) Hepatopancreatoduodenectomy could be allowed for patients with advanced intrahepatic cholangiocarcinoma. Hepatogastroenterology 54:346–349PubMed Urahashi T, Yamamoto M, Ohtsubo T et al (2007) Hepatopancreatoduodenectomy could be allowed for patients with advanced intrahepatic cholangiocarcinoma. Hepatogastroenterology 54:346–349PubMed
12.
Zurück zum Zitat Weimann A, Varnholt H, Sclitt HJ et al (2000) Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg 87:1182–1187PubMedCrossRef Weimann A, Varnholt H, Sclitt HJ et al (2000) Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg 87:1182–1187PubMedCrossRef
13.
Zurück zum Zitat Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332–2338PubMedCrossRef Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332–2338PubMedCrossRef
14.
Zurück zum Zitat Kim ST, Park JO, Lee J et al (2006) A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106:1339–1346PubMedCrossRef Kim ST, Park JO, Lee J et al (2006) A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106:1339–1346PubMedCrossRef
15.
Zurück zum Zitat Furuse J, Okusaka T, Funakoshi A et al (2006) Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol 36:552–556PubMedCrossRef Furuse J, Okusaka T, Funakoshi A et al (2006) Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol 36:552–556PubMedCrossRef
16.
Zurück zum Zitat Ohtsuka M, Ito H, Kimura F et al (2002) Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 89:1525–1531PubMedCrossRef Ohtsuka M, Ito H, Kimura F et al (2002) Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 89:1525–1531PubMedCrossRef
17.
Zurück zum Zitat Liver Cancer Study Group of Japan (2003) General rules for the clinical and pathological study of primary liver cancer, 2nd English edn. Kanehara, Tokyo, pp 16–17 Liver Cancer Study Group of Japan (2003) General rules for the clinical and pathological study of primary liver cancer, 2nd English edn. Kanehara, Tokyo, pp 16–17
18.
Zurück zum Zitat Nakagawa T, Kamiyama T, Kurauchi N et al (2005) Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 29:728–733PubMedCrossRef Nakagawa T, Kamiyama T, Kurauchi N et al (2005) Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 29:728–733PubMedCrossRef
19.
Zurück zum Zitat Lang H, Sotiropoulos GC, Fruhauf NR et al (2005) Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 241:134–143PubMed Lang H, Sotiropoulos GC, Fruhauf NR et al (2005) Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 241:134–143PubMed
20.
Zurück zum Zitat Inoue K, Makuuchi M, Takayama T et al (2000) Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 127:498–505PubMedCrossRef Inoue K, Makuuchi M, Takayama T et al (2000) Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 127:498–505PubMedCrossRef
21.
Zurück zum Zitat Shimada K, Sano T, Sakamoto Y et al (2007) Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases. J Surg Oncol 96:160–165PubMedCrossRef Shimada K, Sano T, Sakamoto Y et al (2007) Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases. J Surg Oncol 96:160–165PubMedCrossRef
22.
Zurück zum Zitat Sobin LH, Wittekind CH (2002) TNM classification of malignant tumours, 6th edn. Wiley, Weat Sussex, pp 81–83 Sobin LH, Wittekind CH (2002) TNM classification of malignant tumours, 6th edn. Wiley, Weat Sussex, pp 81–83
23.
Zurück zum Zitat Yamamoto M, Takasaki K, Yoshikawa T (1999) Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 6:117–121PubMedCrossRef Yamamoto M, Takasaki K, Yoshikawa T (1999) Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 6:117–121PubMedCrossRef
24.
Zurück zum Zitat Miwa S, Miyagawa S, Kobayashi A et al (2006) Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 41:893–900PubMedCrossRef Miwa S, Miyagawa S, Kobayashi A et al (2006) Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 41:893–900PubMedCrossRef
25.
Zurück zum Zitat Nakagohri T, Konishi M, Inoue K et al (2000) Extended right hepatic lobectomy with resection of inferior vena cava and portal vein for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 7:599–602PubMedCrossRef Nakagohri T, Konishi M, Inoue K et al (2000) Extended right hepatic lobectomy with resection of inferior vena cava and portal vein for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 7:599–602PubMedCrossRef
Metadaten
Titel
Surgical Outcome and Prognostic Factors in Intrahepatic Cholangiocarcinoma
verfasst von
Toshio Nakagohri
Taira Kinoshita
Masaru Konishi
Shinichiro Takahashi
Naoto Gotohda
Publikationsdatum
01.12.2008
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 12/2008
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-008-9778-3

Weitere Artikel der Ausgabe 12/2008

World Journal of Surgery 12/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.